Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Islet cell tumor
Stage/Subtype:  glucagonoma
Trial Type:  Treatment
Results 1-15 of 15 for your search:
Start Over
Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16866B, NCI-2015-01656, NCT01342354
Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 11I03, NCI-2011-02939, NCT01465659
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients with Pancreatic Neuroendocrine Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 andover
Trial IDs: 201303150, NCI-2013-00641, NCT01784861
Cabozantinib-s-Malate in Treating Patients with Advanced Pancreatic Neuroendocrine or Carcinoid Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-274, NCI-2012-00539, NCT01466036
Bevacizumab, Capecitabine, and Temozolomide in Treating Patients with Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NET0012, NCI-2011-03497, 22412, END0012, SU-10282011-8571, NCT01525082
Temozolomide with or without Capecitabine in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2211, NCI-2012-02007, NCT01824875
Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-14-3, NCI-2014-01996, HS-14-00583, NCT02259725
Mutation-Targeted Therapy with Sunitinib Malate or Everolimus in Treating Patients with Advanced Neuroendocrine Tumors of the Gastrointestinal Tract or Pancreas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0040, NCI-2015-00091, 150040, 339636, P141605, NCT02315625
Ribociclib in Treating Patients with Advanced Neuroendocrine Tumors of Foregut Origin
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0371, NCI-2015-01017, NCT02420691
Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18141, NCI-2015-01782, 15.04.0041, NCT02575300
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-158, NCI-2015-02278, 2015-002067-41, NCT02628067
MLN0128 and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0665, NCI-2014-01107, 9585, NCT02159989
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, NCT02631733
68Ga-DOTA-JR11and 177Lu-DOTA-JR11 PET/CT in Diagnosing and Treating Patients with Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 15-161, NCI-2015-02110, NCT02609737
Start Over